Compass Therapeutics (CMPX) Payables (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Payables data on file, last reported at $906000.0 in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 42.55% year-over-year to $906000.0; the trailing twelve-month figure through Mar 2026 stood at $906000.0 (down 42.55% YoY), and the FY2025 full-year result was $1.6 million, down 29.52% from the prior year.
• Payables declined to $906000.0 in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $6.5 million in Q2 2022 to a low of $257000.0 in Q1 2022.
• A 5-year average of $2.1 million and a median of $1.6 million in 2025 frame the typical range for Payables.
• Peak annual rise in Payables reached 337.74% in 2023, while the deepest fall reached 88.92% in 2023.
• Tracing CMPX's Payables over 5 years: stood at $3.4 million in 2022, then rose by 20.93% to $4.1 million in 2023, then tumbled by 45.01% to $2.2 million in 2024, then declined by 29.52% to $1.6 million in 2025, then plunged by 42.84% to $906000.0 in 2026.
• Business Quant data shows CMPX's Payables at $906000.0 in Q1 2026, $1.6 million in Q4 2025, and $3.1 million in Q3 2025.